Sign up Australia
Proactive Investors - Run By Investors For Investors

Pearson out in the cold as Deutsche Bank takes a shine to information providers

The information publishing sector is in rude health, according to Deutsche Bank
Data, data, data
Professional services firms are more willing to spend on new products

Deutsche Bank has taken a look at European information providers and come away impressed.

The bank's publishing sector specialist Mark Braley has eschewed watching the World Cup, preferring to meet or speak with a wide range of professional information executives and concluded that the vast majority of professional information markets remain healthy, supported by improving fundamentals.

READ: UBS cuts RELX to ‘sell’

“In a mid-late cycle environment, professional services firms are more willing to spend on new products and B2B [business-to-business] marketing, while companies are launching new work-flow tools, with the cost of development coming down,” Deutsche Bank said.

The bank has 'buy' recommendations for Relx PLC (LON:REL) – the company formerly known as Reed Elsevier – and Ascential PLC (LON:ASCL) but recommends selling Pearson PLC (LON:PSON), despite increasing the latter's target price to 574p from 525p.

Deutsche has a target price of 1,820p on Relx, up from 1,750p previously, while the price target for Ascential has been bumped up to 460p from 425p.

READ: Ascential acquires digital marketing business WARC ahead of revamped Cannes Lions Festival

Shares in Ascential currently trade at 451.4p, down 1.2p on the day, while Pearson currently trades at 913.8p (up 14.4p) and Relx at 1,688p (up 30p).

View full PSON profile View Profile

Pearson plc Timeline

Related Articles

Students in a class
August 27 2018
The company is gaining traction in Asia where people are looking to take language courses to work or study internationally
Marketing and public relations
April 04 2018
"Our Beyond, MBooth and Publitek agencies have been stand-out performers, whilst we have achieved solid performances pretty much across the portfolio"
April 16 2018
Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use